tourmaline-mm3: undetectable mrd as an endpoint for maintenance therapy
Published 4 years ago • 79 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
2:07
key findings of the pooled analysis of the tourmaline-mm3 and mm4 trials
-
2:54
tourmaline-mm4: oral ixazomib maintenance for myeloma
-
4:48
overview of the final analysis of the phase iii tourmaline-mm1 trial
-
3:03
prognostic importance of mrd: results of tourmaline-mm4 trial for ndmm
-
1:40
long-term follow-up of the tourmaline-mm1 trial
-
1:02
maintenance therapy following treatment for amyloidosis
-
3:03
what is tasquinimod?
-
1:49
bringing precision medicine and mrd into clinical strategies
-
4:19
tourmaline-mm3 and 4: ixazomib as maintenance therapy in myeloma patients
-
6:33
the phase 3 tourmaline-mm2 trial
-
2:03
discover the reliability of mindray 3-part hematology analyzer
-
9:57
measurable residual disease evaluation during ixazomib maintenance in ndmm: tourmaline-mm3 and -mm4
-
15:38
new tools for multiple myeloma treatment monitoring
-
15:29
terumo blood and cell technologies
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
13:38
terumo blood and cell technologies
-
1:22
long-term follow-up results of tourmaline-mm2: ird vs pbo-rd in multiple myeloma
-
2:21
overview of the tourmaline-mm1 study in relapsed/refractory multiple myeloma